Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYR | P14679 | 2/20 | 0.40 |
| ▸ | ERN1 | O75460 | 10/20 | 0.39 |
| ▸ | TRIM24 | O15164 | 2/20 | 0.36 |
| ▸ | TRIM33 | Q9UPN9 | 2/20 | 0.36 |
| ▸ | CDK1 | P06493 | 1/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.34 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.34 |
| ▸ | PRKDC | P78527 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL723126 | 0.79 | TYR (0.53) | TYRERN1TRIM24TRIM33 | |
| SCHEMBL29973971 | 0.79 | TYR (0.53) | TYRERN1TRIM24TRIM33 | |
| Hydrochloric Acid SCHEMBL28927068 | 0.78 | TYR (0.52) | TYRERN1TRIM24TRIM33 | |
| SCHEMBL17660183 | 0.77 | ERN1 (0.52) | TYRERN1TRIM24TRIM33CDK1 | |
| SCHEMBL441302 | 0.74 | ERN1 (0.50) | TYRERN1TRIM24TRIM33CDK1 | |
| SCHEMBL4289408 | 0.74 | ERN1 (0.54) | TYRERN1TRIM24TRIM33CDK1 | |
| SCHEMBL23829700 | 0.73 | RORC (0.45) | TYRERN1TRIM24TRIM33CDK1 | |
| SCHEMBL12813947 | 0.73 | ERN1 (0.50) | TYRERN1TRIM24TRIM33CDK1 | |
| SCHEMBL31114205 | 0.73 | ERN1 (0.50) | TYRERN1TRIM24TRIM33CDK1 | |
| SCHEMBL15978282 | 0.71 | TYR (0.53) | TYRERN1TRIM24TRIM33 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180065917-A1 | IMMUNE CHECKPOINT INHIBITORS, COMPOSITIONS AND METHODS THEREOF | POLARIS PHARMACEUTICALS, INC. (JP) | 2018-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180065917-A1 | IMMUNE CHECKPOINT INHIBITORS, COMPOSITIONS AND METHODS THEREOF | CD274, PDCD1, PDCD1LG2 | TYR 1842/4885ERN1 1567/4885TRIM24 2231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.